Management of Relapsed/Refractory Epithelial Ovarian Cancer: Current Standards and Novel Approaches
Approximately 60% to 70% of epithelial ovarian cancers are diagnosed at an advanced stage. Treatment of advanced disease involves cytoreductive surgery followed by systemic treatment with paclitaxel and platinum. Overall response rates are high, ranging from 70–80%; however, 70–80% of responders wil...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2007-12-01
|
| Series: | Taiwanese Journal of Obstetrics & Gynecology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1028455908600078 |
| _version_ | 1818480008011710464 |
|---|---|
| author | Hao Lin Chan-Chao Changchien |
| author_facet | Hao Lin Chan-Chao Changchien |
| author_sort | Hao Lin |
| collection | DOAJ |
| description | Approximately 60% to 70% of epithelial ovarian cancers are diagnosed at an advanced stage. Treatment of advanced disease involves cytoreductive surgery followed by systemic treatment with paclitaxel and platinum. Overall response rates are high, ranging from 70–80%; however, 70–80% of responders will relapse and require further systemic chemotherapy. Patients who experience disease relapse with platinum-free interval of less than 6 months are considered as platinum-refractory/resistant individuals. In this clinical setting, agents with non-cross-resistance to first-line therapy and favorable toxicity profiles are usually chosen. In the management of relapsed patients with platinum-free interval over 6 months, the generally accepted recommendation is retreatment with a platinum plus paclitaxel combination. In general, treatment of recurrent disease is palliative and is initiated with the goals of controlling disease-related symptoms, limiting treatment-related toxicity, maintaining or improving quality of life, delaying time to progression, and prolonging survival. A number of currently available and novel investigating agents in recurrent epithelial ovarian cancer will be reviewed in this context. |
| first_indexed | 2024-12-10T11:17:23Z |
| format | Article |
| id | doaj.art-6db11e1ba8a64b70ac7ed46c8026c2b2 |
| institution | Directory Open Access Journal |
| issn | 1028-4559 |
| language | English |
| last_indexed | 2024-12-10T11:17:23Z |
| publishDate | 2007-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Taiwanese Journal of Obstetrics & Gynecology |
| spelling | doaj.art-6db11e1ba8a64b70ac7ed46c8026c2b22022-12-22T01:51:07ZengElsevierTaiwanese Journal of Obstetrics & Gynecology1028-45592007-12-0146437938810.1016/S1028-4559(08)60007-8Management of Relapsed/Refractory Epithelial Ovarian Cancer: Current Standards and Novel ApproachesHao LinChan-Chao ChangchienApproximately 60% to 70% of epithelial ovarian cancers are diagnosed at an advanced stage. Treatment of advanced disease involves cytoreductive surgery followed by systemic treatment with paclitaxel and platinum. Overall response rates are high, ranging from 70–80%; however, 70–80% of responders will relapse and require further systemic chemotherapy. Patients who experience disease relapse with platinum-free interval of less than 6 months are considered as platinum-refractory/resistant individuals. In this clinical setting, agents with non-cross-resistance to first-line therapy and favorable toxicity profiles are usually chosen. In the management of relapsed patients with platinum-free interval over 6 months, the generally accepted recommendation is retreatment with a platinum plus paclitaxel combination. In general, treatment of recurrent disease is palliative and is initiated with the goals of controlling disease-related symptoms, limiting treatment-related toxicity, maintaining or improving quality of life, delaying time to progression, and prolonging survival. A number of currently available and novel investigating agents in recurrent epithelial ovarian cancer will be reviewed in this context.http://www.sciencedirect.com/science/article/pii/S1028455908600078relapsed ovarian cancer |
| spellingShingle | Hao Lin Chan-Chao Changchien Management of Relapsed/Refractory Epithelial Ovarian Cancer: Current Standards and Novel Approaches Taiwanese Journal of Obstetrics & Gynecology relapsed ovarian cancer |
| title | Management of Relapsed/Refractory Epithelial Ovarian Cancer: Current Standards and Novel Approaches |
| title_full | Management of Relapsed/Refractory Epithelial Ovarian Cancer: Current Standards and Novel Approaches |
| title_fullStr | Management of Relapsed/Refractory Epithelial Ovarian Cancer: Current Standards and Novel Approaches |
| title_full_unstemmed | Management of Relapsed/Refractory Epithelial Ovarian Cancer: Current Standards and Novel Approaches |
| title_short | Management of Relapsed/Refractory Epithelial Ovarian Cancer: Current Standards and Novel Approaches |
| title_sort | management of relapsed refractory epithelial ovarian cancer current standards and novel approaches |
| topic | relapsed ovarian cancer |
| url | http://www.sciencedirect.com/science/article/pii/S1028455908600078 |
| work_keys_str_mv | AT haolin managementofrelapsedrefractoryepithelialovariancancercurrentstandardsandnovelapproaches AT chanchaochangchien managementofrelapsedrefractoryepithelialovariancancercurrentstandardsandnovelapproaches |